Thus, we conclude that CB2-specific synthetic cannabinoids that do not possess psychoactivity can be developed to design novel therapies against breast cancer growth and metastasis by blocking CXCR4/CXCL12-induced signaling. The gene discussed is CXCL12; the disease is breast cancer.